Bayhill Therapeutics Inc is categorized under Commercial Biotechnical Research in Palo Alto, CA and active since 2002.
Bayhill Therapeutics Inc was established in 2002, and today employs 1 to 4, earning $1.000.000 to $2.499.999 per year. This is a Commercial Biotechnical Research business, which does work in the B2B market, and is classified as a Commercial Biotechnical Research, under code number 541711 by the NAICS.
If you are seeking more information, feel free to contact Hideki Garren at the company’s single location by writing to 1804 Embarcadero Road # 201, Palo Alto, California CA 94303 or by phoning (650) 320-2800. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Bayhill Therapeutics Inc |
| Contact Person: | Hideki Garren |
| Address: | 1804 Embarcadero Road # 201, Palo Alto, California 94303 |
| Phone Number: | (650) 320-2800 |
| Annual Revenue (USD): | $1.000.000 to $2.499.999 |
| Founded: | 2002 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Commercial Biotechnical Research |
| SIC Code: | 8731 |
| NAICS Code: | 541711 |
| Share This Business: |
Bayhill Therapeutics Inc was started in 2002 to provide professional Commercial Biotechnical Research under the SIC code 8731 and NAICS code 541711. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $1.000.000 to $2.499.999 per annum.
Feel free to contact Hideki Garren for inquiries that concern Bayhill Therapeutics Inc by calling the company number (650) 320-2800, as your correspondence is most welcome. Additionally, the physical location of the single location of Bayhill Therapeutics Inc can be found at the coordinates 37.451234,-122.116857 as well as the street address 1804 Embarcadero Road # 201 in Palo Alto, California 94303.
For its online presence, you may visit Bayhill Therapeutics Inc’s website at and engage with its social media outlets through on Twitter and on Facebook.